Revenue
2021
2022
2024
Altamira Therapeutics Ltd. (CYTOF)
Price$0.0710Cached quote
Net income
2018
2019
2020
2021
2022
2023
2024
Free cash flow
2022
2024
Total cash / debt
CashTotal debt
2021
2022
2023
2024
Financial statements
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | — | $0 | $0 | — | — | — | — | — | — |
| Research & development | $3.7M | $3.4M | $15.3M | $3.5M | — | — | — | — | — | — |
| Operating expenses | $6.9M | $6.6M | $18.9M | $7.5M | — | — | — | — | — | — |
| Operating income | −$6.9M | −$6.6M | −$18.9M | −$7.5M | — | — | — | — | — | — |
| EBITDA | −$6.7M | −$6.5M | −$18.7M | −$7.3M | — | — | — | — | — | — |
| Net income | −$8.5M | −$4.3M | −$27.8M | −$18.7M | −$8.2M | −$6.6M | −$11.5M | — | — | — |
| Basic EPSper basic share | -$2.99 | -$8.77 | -$610.03 | -$563.52 | -$544.00 | -$912.00 | -$5,784.00 | — | — | — |
| Diluted EPSper diluted share | -$2.99 | -$8.77 | -$610.03 | -$563.52 | -$544.00 | -$912.00 | -$5,784.00 | — | — | — |
Owners
Reported shareholders